|
1
|
Alfalogy E, Mahfouz S, Elmedany S, Hariri
N and Fallatah S: Chronic low back pain: Prevalence, impact on
quality of life, and predictors of future disability. Cureus.
15(e45760)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kahere M, Hlongwa M and Ginindza TG: A
scoping review on the epidemiology of chronic low back pain among
adults in sub-saharan africa. Int J Environ Res Public Health.
19(2964)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nicol V, Verdaguer C, Daste C, Bisseriex
H, Lapeyre É, Lefèvre-Colau MM, Rannou F, Rören A, Facione J and
Nguyen C: Chronic low back pain: A narrative review of recent
international guidelines for diagnosis and conservative treatment.
J Clin Med. 12(1685)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hnatešen D, Pavić R, Radoš I, Dimitrijević
I, Budrovac D, Čebohin M and Gusar I: Quality of life and mental
distress in patients with chronic low back pain: A cross-sectional
study. Int J Environ Res Public Health. 19(10657)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Onuţu AH: Duloxetine, an antidepressant
with analgesic properties-A preliminary analysis. Rom J Anaesth
Intensive Care. 22:123–128. 2015.PubMed/NCBI
|
|
6
|
Dhaliwal JS, Spurling BC and Molla M:
Duloxetine. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright ©. 2024, StatPearls Publishing LLC.; 2024.
|
|
7
|
Skljarevski V, Zhang S, Desaiah D, Alaka
KJ, Palacios S, Miazgowski T and Patrick K: Duloxetine versus
placebo in patients with chronic low back pain: A 12-week,
fixed-dose, randomized, double-blind trial. J Pain. 11:1282–1290.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Weng C, Xu J, Wang Q, Lu W and Liu Z:
Efficacy and safety of duloxetine in osteoarthritis or chronic low
back pain: A systematic review and meta-analysis. Osteoarthritis
Cartilage. 28:721–734. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hirase T, Hirase J, Ling J, Kuo PH,
Hernandez GA, Giwa K and Marco R: Duloxetine for the treatment of
chronic low back pain: A systematic review of randomized
placebo-controlled trials. Cureus. 13(e15169)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Gift AG: Visual analogue scales:
Measurement of subjective phenomena. Nur Res. 38:286–288.
1989.PubMed/NCBI
|
|
12
|
Cleeland CS and Ryan KM: Pain assessment:
Global use of the brief pain inventory. Ann Acad Med Singap.
23:129–138. 1994.PubMed/NCBI
|
|
13
|
Stratford PW and Riddle DL: A roland
morris disability questionnaire target value to distinguish between
functional and dysfunctional states in people with low back pain.
Physiother Can. 68:29–35. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hays RD, Sherbourne CD and Mazel RM: The
rand 36-item health survey 1.0. Health Econ. 2:217–227.
1993.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Srikrishna S, Robinson D and Cardozo L:
Validation of the patient global impression of improvement (PGI-I)
for urogenital prolapse. Int Urogynecol J. 21:523–528.
2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Raskin J, Wiltse CG, Siegal A, Sheikh J,
Xu J, Dinkel JJ, Rotz BT and Mohs RC: Efficacy of duloxetine on
cognition, depression, and pain in elderly patients with major
depressive disorder: An 8-week, double-blind, placebo-controlled
trial. Am J Psychiatry. 164:900–909. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Stein DJ, Phillips KA, Bolton D, Fulford
KW, Sadler JZ and Kendler KS: What is a mental/psychiatric
disorder? From DSM-IV to DSM-V. Psychol Med. 40:1759–1765.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nixon N, Guo B, Garland A, Kaylor-Hughes
C, Nixon E and Morriss R: The bi-factor structure of the 17-item
hamilton depression rating scale in persistent major depression;
dimensional measurement of outcome. PLoS One.
15(e0241370)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Higgins JPT, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JAC:
Cochrane Bias Methods Group; Cochrane Statistical Methods Group.
The Cochrane collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Schukro RP, Oehmke MJ, Geroldinger A,
Heinze G, Kress HG and Pramhas S: Efficacy of duloxetine in chronic
low back pain with a neuropathic component: A randomized,
double-blind, placebo-controlled crossover trial. Anesthesiology.
124:150–158. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Samadi A, Salehian R, Kiani D and Jolfaei
AG: Effectiveness of duloxetine on severity of pain and quality of
life in chronic low back pain in patients who had posterior spinal
fixation. J Orth Trauma Rehabil. 6(144)2021.
|
|
22
|
Konno S, Oda N, Ochiai T and Alev L:
Randomized, double-blind, placebo-controlled phase III trial of
duloxetine monotherapy in Japanese patients with chronic low back
pain. Spine (Phila Pa 1976). 41:1709–1717. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Skljarevski V, Desaiah D, Liu-Seifert H,
Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH and Backonja
M: Efficacy and safety of duloxetine in patients with chronic low
back pain. Spine (Phila Pa 1976). 35:E578–E585. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Skljarevski V, Ossanna M, Liu-Seifert H,
Zhang Q, Chappell A, Iyengar S, Detke M and Backonja M: A
double-blind, randomized trial of duloxetine versus placebo in the
management of chronic low back pain. Eur J Neurol. 16:1041–1048.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Brown JP and Boulay LJ: Clinical
experience with duloxetine in the management of chronic
musculoskeletal pain. A focus on osteoarthritis of the knee. Ther
Adv Musculoskelet Dis. 5:291–304. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rodrigues-Amorim D, Olivares JM, Spuch C
and Rivera-Baltanás T: A systematic review of efficacy, safety, and
tolerability of duloxetine. Front Psychiatry.
11(554899)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jia Z, Yu J, Zhao C, Ren H and Luo F:
Outcomes and predictors of response of duloxetine for the treatment
of persistent idiopathic dentoalveolar pain: A retrospective
multicenter observational study. J Pain Res. 15:3031–3041.
2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yasuda H, Hotta N, Nakao K, Kasuga M,
Kashiwagi A and Kawamori R: Superiority of duloxetine to placebo in
improving diabetic neuropathic pain: Results of a randomized
controlled trial in Japan. J Diabetes Investig. 2:132–139.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Obata H: Analgesic mechanisms of
antidepressants for neuropathic pain. Int J Mol Sci.
18(2483)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Onda A and Kimura M: Reduction in anxiety
during treatment with exercise and duloxetine is related to
improvement of low back pain-related disability in patients with
non-specific chronic low back pain. Fukushima J Med Sci.
66:148–155. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ferreira GE, McLachlan AJ, Lin C-WC, Zadro
JR, Abdel-Shaheed C, O'Keeffe M and Maher CG: Efficacy and safety
of antidepressants for the treatment of back pain and
osteoarthritis: Systematic review and meta-analysis. BMJ.
372(m4825)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mazza M, Mazza O, Pazzaglia C, Padua L and
Mazza S: Escitalopram 20 mg versus duloxetine 60 mg for the
treatment of chronic low back pain. Expert Opin Pharmacother.
11:1049–1052. 2010.PubMed/NCBI View Article : Google Scholar
|
